{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:05:50Z","timestamp":1790514350297,"version":"4.1.0"},"reference-count":208,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the central nervous system omega-3 fatty acids modulate cell signaling and affect dopaminergic and serotonergic pathways. On this basis, a new application for omega-3 fatty acids has been proposed, concerning the treatment of several psychiatric disorders. The present article is an update of a previous systematic review and is aimed to provide a complete report of data published in the period between 1980 and 2019 on efficacy and tolerability of omega-3 fatty acids in psychiatric disorders. In July 2019, an electronic search on PUBMED, Medline and PsychINFO of all RCTs, systematic reviews and meta-analyses on omega-3 fatty acids and psychiatric disorders without any filter or MESH restriction was performed. After eligibility processes, the final number of records included in this review was 126. One hundred and two of these studies were RCTs, while 24 were reviews and meta-analyses. The role of omega-3 fatty acids was studied in schizophrenia, major depression, bipolar disorder, anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, eating disorders, substance use disorder and borderline personality disorder. The main evidence of the efficacy of omega-3 fatty acids has been obtained in treating depressive symptoms in patients with major depression and, to a lesser degree, bipolar depression. Some efficacy was also found in early phases of schizophrenia in addition to antipsychotic treatment, but not in the chronic phases of psychosis. Small beneficial effects of omega-3 fatty acids were observed in ADHD and positive results were reported in a few trials on core symptoms of borderline personality disorder. For other psychiatric disorders results are inconsistent.<\/jats:p>","DOI":"10.3390\/ijms20215257","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T03:20:36Z","timestamp":1571973636000},"page":"5257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?"],"prefix":"10.3390","volume":"20","author":[{"given":"Paola","family":"Bozzatello","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Mantelli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-8000","authenticated-orcid":false,"given":"Silvio","family":"Bellino","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0115426506021004323","article-title":"Current clinical applications of omega-6 and omega-3 fatty acids","volume":"21","author":"Lee","year":"2006","journal-title":"Nutr. Clin. Pr."},{"key":"ref_2","first-page":"1","article-title":"The Omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) reverses corticosterone-induced changes in cortical neurons","volume":"6","author":"Pusceddu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.arr.2017.09.001","article-title":"Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition","volume":"40","author":"Calder","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fimmu.2019.00837","article-title":"Clinical advances in immunonutrition and atherosclerosis: A review","volume":"10","author":"Lapuente","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ajcn\/70.3.560s","article-title":"Essential fatty acids in health and chronic disease","volume":"70","author":"Simopoulos","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_6","first-page":"34","article-title":"n-3 fatty acids and the immune system in autoimmunity","volume":"4","author":"Ergas","year":"2002","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4088\/JCP.15r09925","article-title":"Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: A review of biomarker and treatment studies","volume":"77","author":"Saunders","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/jn\/129.11.2088","article-title":"Docosahexanoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotrasmitters in frontal cortex caused by a linoleic and alpha-linoleic acid deficient diet in formula-fed piglets","volume":"129","author":"Innis","year":"1999","journal-title":"J. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/nu2020128","article-title":"Oiling the brain: A review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan","volume":"2","author":"Sinn","year":"2010","journal-title":"Nutrients"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bozzatello, P., Brignolo, E., De Grandi, E., and Bellino, S. (2016). Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data. J. Clin. Med., 5.","DOI":"10.3390\/jcm5080067"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.psc.2012.12.002","article-title":"Omega-3 fatty acids in psychiatry","volume":"36","author":"Mischoulon","year":"2013","journal-title":"Psychiatr. Clin. N. Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0920-9964(94)90084-1","article-title":"A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases","volume":"12","author":"Glen","year":"1994","journal-title":"Schizophr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/oxfordjournals.schbul.a007140","article-title":"Reduced red blood cell membrane essential polyunsatu- rated fatty acids in first episode schizophrenia at neuroleptic-naive baseline","volume":"30","author":"Reddy","year":"2004","journal-title":"Schizophr. Bull."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/eip.12151","article-title":"Polyunsaturated fatty acids in emerging psychosis: A safer alternative?","volume":"8","author":"Amminger","year":"2014","journal-title":"Early Interv. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2018.09.022","article-title":"Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium","volume":"204","author":"Cadenhead","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.plefa.2010.07.001","article-title":"Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia","volume":"83","author":"Sethom","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.psychres.2010.07.049","article-title":"Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia","volume":"186","author":"Sumiyoshi","year":"2011","journal-title":"Psychiatry Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/070674371305800705","article-title":"Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: A post hoc subgroup analysis of a double-blind, randomized controlled trial","volume":"58","author":"Amminger","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1038\/ncomms8934","article-title":"Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study","volume":"6","author":"Amminger","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/mp.2013.7","article-title":"Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis","volume":"19","author":"Smesny","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamapsychiatry.2016.2902","article-title":"Effect of \u03c9-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders","volume":"74","author":"McGorry","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4088\/JCP.v68n1206","article-title":"Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial","volume":"68","author":"Berger","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/sj.npp.1301628","article-title":"Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study","volume":"33","author":"Berger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pscychresns.2009.12.003","article-title":"Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study","volume":"182","author":"Wood","year":"2010","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2014.06.004","article-title":"A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia","volume":"158","author":"Emsley","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpsychires.2015.11.013","article-title":"A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia","volume":"73","author":"Trafalska","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.plefa.2017.05.004","article-title":"Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial","volume":"121","author":"Pawelczyk","year":"2017","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pnpbp.2017.12.008","article-title":"Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial","volume":"83","author":"Pawelczyk","year":"2018","journal-title":"Prog. Neuropsychopharm. Biol. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0920-9964(00)00083-9","article-title":"Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia","volume":"49","author":"Peet","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J. Psychiat. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_34","first-page":"103","article-title":"Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia","volume":"18","author":"Jamilian","year":"2014","journal-title":"Glob. J. Health Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/tp.2013.110","article-title":"A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia","volume":"3","author":"Bentsen","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2017.08.026","article-title":"Effects of Omega-3 in the treatment of violent schizophrenia patients","volume":"195","author":"Qiao","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1176\/appi.ps.201800511","article-title":"Predictors of hospitalization of individuals with first-episode psychosis: Data from a 2-year follow-up of the raise-ETP","volume":"7","author":"Robinson","year":"2019","journal-title":"Psychiatr. Serv."},{"key":"ref_39","first-page":"CD001257","article-title":"Polyunsaturated fatty acid supplementation for schizophrenia","volume":"19","author":"Joy","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.4088\/JCP.v67n1217","article-title":"Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry","volume":"67","author":"Freeman","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0b013e318248b7bb","article-title":"Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies","volume":"32","author":"Berger","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2710.2011.01265.x","article-title":"A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia","volume":"37","author":"Akter","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Agostoni, C., Nobile, M., Ciappolino, V., Delvecchio, G., Tesei, A., Turolo, S., Crippa, A., Mazzocchi, A., Altamura, C.A., and Brambilla, P. (2017). The Role of omega-3 fatty acids in developmental psychopathology: A systematic review on early psychosis, Autism, and ADHD. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122608"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/schbul\/sbx162","article-title":"Nutritional deficiencies and clinical correlates in first-episode psychosis: A systematic review and meta-analysis","volume":"44","author":"Carney","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_45","first-page":"16","article-title":"Nutritional supplements in psychotic disorders","volume":"45","year":"2017","journal-title":"Actas Esp. Psiquiatr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0006-3223(97)00206-0","article-title":"Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients","volume":"43","author":"Peet","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biopsych.2010.03.018","article-title":"A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression","volume":"68","author":"Lin","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"ref_48","first-page":"219578","article-title":"Fish consumption moderates depressive symptomatology in elderly men and women from the IKARIA study","volume":"2011","author":"Chrysohoou","year":"2010","journal-title":"Cardiol. Res. Pr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.plefa.2012.03.003","article-title":"Associations between omega-3 poly-unsaturated fatty acids from fish consumption and severity of depressive symptoms: An analysis of the 2005\u20132008 national health and nutrition examination survey","volume":"86","author":"Hoffmire","year":"2012","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3945\/jn.113.179119","article-title":"\u03a9\u22123 fatty acid intakes are inversely related to elevated depressive symptoms among United States women","volume":"143","author":"Beydoun","year":"2013","journal-title":"J. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000343970","article-title":"Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders","volume":"28","author":"Song","year":"2013","journal-title":"Mod. Trends Pharmacopsychiatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2014.06.032","article-title":"Inflammatory cytokine-associated depression","volume":"1617","author":"Lotrich","year":"2015","journal-title":"Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.plipres.2015.12.003","article-title":"The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer\u2019s disease: Acting separately or synergistically?","volume":"62","author":"Song","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpsychires.2015.12.007","article-title":"Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression","volume":"75","author":"Chhetry","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Villegas, A., \u00c1lvarez-P\u00e9rez, J., Toledo, E., Salas-Salvad\u00f3, J., Ortega-Azor\u00edn, C., Zome\u00f1o, M.D., Vioque, J., Mart\u00ednez, J.A., Romaguera, D., and P\u00e9rez-L\u00f3pez, J. (2018). Seafood consumption, omega-3 fatty acids intake, and life-time prevalence of depression in the PREDIMED-plus trial. Nutrients, 10.","DOI":"10.3390\/nu10122000"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.ajp.159.3.477","article-title":"Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder","volume":"159","author":"Nemets","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archpsyc.59.10.913","article-title":"A dose-ranging study of the effects of ethyl- eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs","volume":"59","author":"Peet","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1067\/mob.2003.275","article-title":"Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing","volume":"188","author":"Llorente","year":"2003","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1176\/appi.ajp.160.5.996","article-title":"A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression","volume":"160","author":"Marangell","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0924-977X(03)00032-4","article-title":"Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial","volume":"13","author":"Su","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.plefa.2004.11.004","article-title":"Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression","volume":"72","author":"Silvers","year":"2005","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/ajp.2006.163.6.1098","article-title":"Omega-3 treatment of childhood depression: A controlled, double-blind pilot study","volume":"163","author":"Nemets","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.pnpbp.2007.06.004","article-title":"Fish oil supplementation in the treatment of major depression: A randomised double- blind placebo-controlled trial. Prog","volume":"31","author":"Grenyer","year":"2007","journal-title":"Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jad.2007.12.228","article-title":"Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study","volume":"110","author":"Freeman","year":"2008","journal-title":"J. Affect. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/00048670701827275","article-title":"Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder","volume":"42","author":"Jazayeri","year":"2008","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00048670701827267","article-title":"Omega-3 fatty acids as a treatment for perinatal depression: Randomized double-blind placebo-controlled trial","volume":"42","author":"Rees","year":"2008","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S0007114507801097","article-title":"No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial","volume":"99","author":"Rogers","year":"2008","journal-title":"Br. J. Nutr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pnpbp.2008.10.003","article-title":"Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample","volume":"33","author":"Doornbos","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3945\/ajcn.2008.26749","article-title":"Ethyleicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle- aged women: A double-blind, placebo-controlled, randomized clinical trial","volume":"89","author":"Lucas","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.4088\/JCP.08m04603","article-title":"A double-blind, randomized controlled trial of ethyl- eicosapentaenoate for major depressive disorder","volume":"70","author":"Mischoulon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.2010.1507","article-title":"DOMInO Investigative Team, Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: A randomized controlled trial","volume":"304","author":"Makrides","year":"2010","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/07315724.2010.10719817","article-title":"Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: A double-blind, placebo-controlled, randomized clinical trial","volume":"29","author":"Rondanelli","year":"2010","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12603-011-0011-y","article-title":"Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: Effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life","volume":"15","author":"Rondanelli","year":"2011","journal-title":"J. Nutr. Health Aging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4088\/JCP.10m05966blu","article-title":"The efficacy of omega-3 supplementation for major depression: A randomized controlled trial","volume":"72","author":"Turecki","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00406-011-0191-9","article-title":"The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: A double-blind, randomized, placebocontrolled study","volume":"261","author":"Tajalizadekhoob","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0269881111424928","article-title":"Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals","volume":"26","author":"Antypa","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JCP.0b013e31823f3b5f","article-title":"Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder","volume":"32","author":"Gertsik","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_78","first-page":"585","article-title":"Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression","volume":"46","author":"Krawczyk","year":"2012","journal-title":"Psychiatr. Pol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2891-11-82","article-title":"Comparison between the AA\/EPA ratio in depressed and non depressed elderly females: Omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters","volume":"11","author":"Rizzo","year":"2012","journal-title":"Nutr. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.euroneuro.2012.08.003","article-title":"Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: A randomized, doubleblind, placebo-controlled trial","volume":"23","author":"Karamati","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_81","first-page":"1","article-title":"The mothers, Omega-3, and mental health study: A double-blind, randomized controlled trial","volume":"313","author":"Mozurkewich","year":"2013","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijnss.2014.10.005","article-title":"Pilot trial evaluating maternal docosahexaenoic acid consumption during pregnancy: Decreased postpartum depressive symptomatology","volume":"1","author":"Judge","year":"2014","journal-title":"Int. J. Nursing Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.psychres.2015.05.072","article-title":"Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial","volume":"229","author":"Ginty","year":"2015","journal-title":"Psychiatry Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4088\/JCP.14m08986","article-title":"A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression","volume":"76","author":"Mischoulon","year":"2015","journal-title":"J. Clin. Psychiat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000377640","article-title":"Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: A randomized, double-blind, 12-week, placebo-controlled trial in Korea","volume":"66","author":"Park","year":"2015","journal-title":"Ann. Nutr. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10802-016-0203-3","article-title":"Psychoeducational psychotherapy and omega-3 supplementation improve co-occurring behavioral problems in youth with depression: Results from a pilot RCT","volume":"45","author":"Young","year":"2017","journal-title":"J. Abnorm. Child. Psychol."},{"key":"ref_87","first-page":"79","article-title":"A Double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression","volume":"26","author":"Gabbay","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2018.05.018","article-title":"Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation","volume":"238","author":"Hsu","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpsychires.2018.09.016","article-title":"Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders\u2014Results from a double-blind, randomized and placebo-controlled clinical trial","volume":"107","author":"Jahangard","year":"2018","journal-title":"J. Psychiatr Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jad.2018.11.039","article-title":"Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial","volume":"245","author":"Tayama","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/mp.2015.22","article-title":"Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder a proof-of-concept study","volume":"21","author":"Rapaport","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/mp.2011.100","article-title":"Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis","volume":"17","author":"Bloch","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., and Caraci, F. (2014). Role of omega-3 fatty acids in the treatment of depressive disorders: A comprehensive meta-analysis of randomized clinical trials. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096905"},{"key":"ref_94","first-page":"CD004692","article-title":"Omega-3 fatty acids for depression in adults","volume":"11","author":"Appleton","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S1461145713001399","article-title":"Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder","volume":"17","author":"Sublette","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jpsychires.2009.06.003","article-title":"Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines","volume":"44","author":"Sarris","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1740-8709.2010.00256.x","article-title":"High dietary ratio of omega-6 to omega-3 polyunsaturated acids during pregnancy and prevalence of post-partum depression","volume":"8","author":"Rocha","year":"2012","journal-title":"Matern. Child. Nutr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0706743716660290","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. complementary and alternative medicine treatments","volume":"61","author":"Ravindran","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e010172","DOI":"10.1136\/bmjopen-2015-010172","article-title":"\u03c9-3 Fatty acids for major depressive disorder in adults: An abridged Cochrane review","volume":"6","author":"Appleton","year":"2016","journal-title":"BMJ Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1192\/bjp.bp.114.160242","article-title":"Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression","volume":"209","author":"Hallahan","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1038\/tp.2016.29","article-title":"Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder","volume":"6","author":"Mocking","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.euroneuro.2017.07.004","article-title":"Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis","volume":"27","author":"Schefft","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jad.2016.12.034","article-title":"The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders","volume":"224","author":"Ciappolino","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/07315724.2009.10719785","article-title":"EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acids supplementation in depression evidence from a meta-analysis of randomized controlled trials","volume":"28","author":"Martins","year":"2009","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4088\/JCP.10m06634","article-title":"Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression","volume":"72","author":"Sublette","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_106","first-page":"8","article-title":"The Psychoneuroimmunological role of omega-3 polyunsaturated fatty acids in major depressive disorder and bipolar disorder","volume":"31","author":"Rutkofsky","year":"2017","journal-title":"Adv. Mind Body Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4088\/JCP.v66n1219b","article-title":"Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder","volume":"66","author":"Chiu","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.psychres.2007.08.021","article-title":"Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder","volume":"160","author":"McNamara","year":"2008","journal-title":"Psychiatry Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1176\/ajp.161.10.1922","article-title":"Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder","volume":"161","author":"Hirashima","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.biopsych.2006.03.056","article-title":"Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder","volume":"60","author":"Keck","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.188.1.46","article-title":"Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study","volume":"188","author":"Frangou","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/JCP.0b013e318266854c","article-title":"Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: A double-blind, randomized add-on clinical trial","volume":"32","author":"Murphy","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.56.5.407","article-title":"Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial","volume":"56","author":"Stoll","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1399-5618.2010.00799.x","article-title":"Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder","volume":"12","author":"Gracious","year":"2010","journal-title":"Bipolar Disord."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.apnu.2008.02.011","article-title":"Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: A systematic review","volume":"22","author":"Turnbull","year":"2008","journal-title":"Arch. Psychiat. Nurs."},{"key":"ref_116","first-page":"CD005169","article-title":"Omega-3 fatty acids for bipolar disorder","volume":"2","author":"Montgomery","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_117","first-page":"39","article-title":"Efficacy of omega-3 fatty acids in mood disorders\u2014A systematic review and metaanalysis","volume":"42","author":"Kraguljac","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4088\/JCP.10r06710","article-title":"Omega-3 for bipolar disorder: Meta-analyses of use in mania and bipolar depression","volume":"73","author":"Sarris","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ynstr.2016.02.003","article-title":"Association between serum C-reactive protein and DSM-IV generalized anxiety disorder in adolescence: Findings from the ALSPAC cohort","volume":"4","author":"Khandaker","year":"2016","journal-title":"Neurobiol. Stress."},{"key":"ref_120","first-page":"1","article-title":"Omega-3 fatty acids and anxiety: A systematic review of the possible mechanisms at play","volume":"28","author":"Polokowski","year":"2018","journal-title":"Nutr. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.psyneuen.2018.07.002","article-title":"Omega-3 polyunsaturated fatty acid levels and dysregulations in biological stress systems","volume":"97","author":"Thesing","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/01.jcp.0000246214.49271.f1","article-title":"n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers","volume":"26","author":"Branchey","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e182327","DOI":"10.1001\/jamanetworkopen.2018.2327","article-title":"Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis","volume":"1","author":"Su","year":"2018","journal-title":"JAMA Netw. Open."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3956(03)00077-3","article-title":"A placebo-controlled cross-over trial of adjunctive EPA in OCD","volume":"38","author":"Fux","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e1015-22","DOI":"10.4088\/JCP.14m09260","article-title":"Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: A randomized, placebo-controlled trial","volume":"76","author":"Matsuoka","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jad.2016.08.005","article-title":"Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements","volume":"205","author":"Matsuoka","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2016.05.054","article-title":"Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: A randomized, double-blind, placebo-controlledtrial","volume":"224","author":"Matsumura","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.pnpbp.2007.10.020","article-title":"Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers","volume":"32","author":"Branchey","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2016.08.021","article-title":"Fatty acid concentrations in patients with posttraumatic stress disorder compared to healthy controls","volume":"205","author":"Mocking","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Alquraan, L., Alzoubi, K.H., Hammad, H., Rababa\u2019h, S.Y., and Mayyas, F. (2019). Omega-3 fatty acids prevent post-traumatic stress disorder-induced memory impairment. Biomolecules, 9.","DOI":"10.3390\/biom9030100"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neulet.2007.01.010","article-title":"Omega-3 fatty acids upregulate adult neurogenesis","volume":"415","author":"Beltz","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1471-4159.2004.02520.x","article-title":"Docosahexaenoic acid promotes neurite growth in hippocampal neurons","volume":"90","author":"Calderon","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.cell.2009.10.020","article-title":"Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory","volume":"139","author":"Kitamura","year":"2009","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Matsuoka, Y., Nishi, D., Nakaya, N., Sone, T., Hamazaki, K., Hamazaki, T., and Koido, Y. (2011). Attenuating posttraumatic distress with omega-3 polyunsaturated fatty acids among disaster medical assistance team members after the Great East Japan Earthquake: The APOP randomized controlled trial. BMC Psychiatry, 11.","DOI":"10.1186\/1471-244X-11-132"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biopsycho.2011.09.012","article-title":"Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: A randomized and placebo controlled trial","volume":"89","author":"Ginty","year":"2012","journal-title":"Biol. Psychol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.nut.2004.07.020","article-title":"Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: A randomized, placebo-controlled, double-blind trial","volume":"21","author":"Hamazaki","year":"2005","journal-title":"Nutrition"},{"key":"ref_137","first-page":"3","article-title":"The effect of omega-3 fatty acids on psychophysiological assessment for the secondary prevention of posttraumatic stress disorder: An open-label pilot study","volume":"4","author":"Matsumura","year":"2012","journal-title":"Glob. J. Health Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/07315724.2003.10719327","article-title":"The effect of flax seed cultivars with differing content of alpha-linolenic acid and lignans on responses to mental stress","volume":"22","author":"Spence","year":"2003","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1194\/jlr.M300217-JLR200","article-title":"Effects of dietary n-3 or n6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats","volume":"44","author":"Song","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/ajcn\/62.4.761","article-title":"Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder","volume":"62","author":"Stevens","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/mp.2016.74","article-title":"Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies","volume":"21","author":"Bonvicini","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_142","first-page":"1","article-title":"The role of marine omega-3 in human neurodevelopment, including autism spectrum disorders and attention-deficit\/hyperactivity disorder\u2014a review","volume":"18","author":"Martins","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mpd.2001.116050","article-title":"A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit\/hyperactivity disorder","volume":"139","author":"Voigt","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0278-5846(01)00254-8","article-title":"A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties","volume":"26","author":"Richardson","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11745-006-1155-0","article-title":"EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors","volume":"38","author":"Stevens","year":"2003","journal-title":"Lipids"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.ejcn.1601830","article-title":"Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit\/hyperactivity disorder\u2014A placebo-controlled double-blind study","volume":"58","author":"Hirayama","year":"2004","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.plefa.2008.04.004","article-title":"Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: A randomised controlled trial","volume":"78","author":"Sinn","year":"2008","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ajcn\/87.5.1170","article-title":"Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: Effect of dietary n-3 fatty acids containing phospholipids","volume":"87","author":"Vaisman","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1087054708316261","article-title":"Omega-3\/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents","volume":"12","author":"Johnson","year":"2009","journal-title":"J. Atten. Disord."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/pch\/14.2.89","article-title":"Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study","volume":"14","author":"Vanasse","year":"2009","journal-title":"Paediatr. Child. Health"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/j.1651-2227.2010.01871.x","article-title":"EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD","volume":"99","author":"Gustafsson","year":"2010","journal-title":"Acta Paediatr."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0883073811435243","article-title":"Combined !3 and !6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment","volume":"27","author":"Perera","year":"2012","journal-title":"J. Child. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.eurpsy.2011.05.004","article-title":"The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension","volume":"27","author":"Manor","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1367493511403953","article-title":"Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties","volume":"15","author":"Milte","year":"2011","journal-title":"J. Child. Health Care"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.plefa.2014.04.004","article-title":"Effect of supplementation with long-chain \u03c9-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit\/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial","volume":"91","author":"Schwanda","year":"2014","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1038\/npp.2015.73","article-title":"Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit\/hyperactivity disorder","volume":"40","author":"Bos","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaac.2011.06.008","article-title":"Omega-3 fatty acid supplementation for the treatment of children with attention-deficit\/hyperactivity disorder symptomatology: Systematic review and meta-analysis","volume":"50","author":"Bloch","year":"2011","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.2012.12070991","article-title":"Nonpharmacological interventions for ADHD: Systematic review and metaanalyses of randomized controlled trials of dietary and psychological treatments","volume":"170","author":"Brandeis","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"ref_159","first-page":"CD007986","article-title":"Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents","volume":"7","author":"Gillies","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MCO.0000000000000140","article-title":"Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder","volume":"18","author":"Gow","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/npp.2017.160","article-title":"Omega-3 polyunsaturated fatty acids in youths with Attention deficit hyperactivity disorder: A systematic review and meta-analysis of clinical trials and biological studies","volume":"43","author":"Chang","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1054\/plef.2000.0186","article-title":"Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders?","volume":"63","author":"Bell","year":"2000","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.plefa.2004.03.008","article-title":"Essential fatty acids and phospholipase A2 in autistic spectrum disorders","volume":"71","author":"Bell","year":"2004","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/plef.2001.0281","article-title":"Plasma fatty acid levels in autistic children","volume":"65","author":"Vancassel","year":"2001","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopsych.2006.05.007","article-title":"Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo controlled pilot study","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10803-010-1078-8","article-title":"A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder","volume":"41","author":"Bent","year":"2011","journal-title":"J. Autism Dev. Disord."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaac.2014.01.018","article-title":"Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in Autism","volume":"53","author":"Bent","year":"2014","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0b013e3182485791","article-title":"Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with Autism spectrum disorders","volume":"32","author":"Yui","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000000260","article-title":"Dietary docosahexaenoic acid supplementation in children with autism","volume":"58","author":"Voigt","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-015-0010-7","article-title":"A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism","volume":"6","author":"Mankad","year":"2015","journal-title":"Mol. Autism"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1007\/s10803-017-3249-3","article-title":"Effect of Omega-3 and -6 supplementation on language in preterm toddlers exhibiting Autism spectrum disorder symptoms","volume":"47","author":"Sheppard","year":"2017","journal-title":"J. Autism Dev. Disord."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2018.10.017","article-title":"A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder","volume":"187","author":"Mazahery","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3945\/jn.116.242354","article-title":"\u03c9-3 fatty acid supplementation does not affect Autism spectrum disorder in children: A systematic review and meta-analysis","volume":"147","author":"Horvath","year":"2017","journal-title":"J. Nutr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mehy.2019.03.012","article-title":"Improving autism perinatal risk factors: A systematic review","volume":"127","author":"Cheng","year":"2019","journal-title":"Med. Hypotheses"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1651-2227.2012.02684.x","article-title":"Omega-3 essential fatty acid status is improved during nutritional rehabilitation of adolescent girls with eating disorders and weight loss","volume":"101","author":"Swenne","year":"2012","journal-title":"Acta Paediatr."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clnu.2011.11.015","article-title":"Anorexia nervosa patients display a deficit in membrane long chain poly-unsaturated fatty acids","volume":"31","author":"Montastier","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/ajcn\/41.5.1054","article-title":"Vitamin E, vitamin A and essential fatty acid status of patients hospitalized for anorexia nervosa","volume":"41","author":"Langan","year":"1985","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_178","first-page":"255","article-title":"Concentration patterns of plasma dehydroepian- drosterone, delta 5-androstenediol and their sulphates, testosterone and cortisol in normal healthy women and in women with anorexia nervosa","volume":"108","author":"Sirinathsinghji","year":"1985","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1651-2227.2011.02400.x","article-title":"Omega-3 polyunsaturated essential fatty acids are associated with depression in adolescents with eating disorders and weight loss","volume":"100","author":"Swenne","year":"2011","journal-title":"Acta Paediatr."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.euroneuro.2016.02.008","article-title":"Contemporary views on the genetics of anorexia nervosa","volume":"26","author":"Shih","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.plefa.2004.03.007","article-title":"A pilot open case series of ethyl EPA supplementation in thetreatment of anorexia nervosa","volume":"71","author":"Ayton","year":"2004","journal-title":"Prostaglandins Leukort. Essent. Fat. Acids"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/eat.10235","article-title":"Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa","volume":"35","author":"Barbarich","year":"2004","journal-title":"Int. J. Eat. Disord."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0924-977X(16)31880-6","article-title":"Polyunsaturated omega-3 fatty acids are not effective for depressive and compulsive symptoms in adolescent girls with anorexia nervosa","volume":"26","author":"Balcerzak","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/10640266.2016.1260379","article-title":"Acceptability and tolerability of omega-3 fatty acids as adjunctive treatment for children and adolescents with eating disorders","volume":"25","author":"Woo","year":"2017","journal-title":"Eat. Disord."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/eat.22964","article-title":"A pilot randomized controlled trial of omega-3 fatty acid supplementation for the treatment of anxiety in adolescents with anorexia nervosa","volume":"51","author":"Manos","year":"2018","journal-title":"Int. J. Eat Disord."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.plefa.2019.01.001","article-title":"Relationship between polyunsaturated fatty acid and eating disorders: Systematic review and meta-analysis","volume":"142","author":"Satogami","year":"2019","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpsychires.2017.03.006","article-title":"Unblending borderline personality and bipolar disorders","volume":"91","author":"Aspesi","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neubiorev.2016.07.017","article-title":"The effect of omega-3 fatty acids on aggression: A meta-analysis","volume":"69","author":"Gajos","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.psychres.2017.12.038","article-title":"Omega-3 supplements reduce self-reported physical aggression in healthy adults","volume":"261","author":"Zaalberg","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11920-018-0894-y","article-title":"Omega-3 supplementation as a dietary intervention to reduce aggressive and antisocial behavior","volume":"20","author":"Choy","year":"2018","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.ajp.160.1.167","article-title":"Omega-3 fatty acid treatment of women with borderline personality disorder: A double blind, placebo-controlled pilot study","volume":"160","author":"Zanarini","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1192\/bjp.bp.106.022707","article-title":"Omega-3 fatty acids supplementation in patients with recurrent self-harm: Single center double bind randomized controlled trial","volume":"190","author":"Hallahan","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0269881113510072","article-title":"Efficacy of omega-3fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid","volume":"28","author":"Bellino","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/ipm.2016.34","article-title":"Lipids and polyunsaturated fatty acid levels in deliberate self-harm: A 10-year follow-up study","volume":"34","author":"Gallagher","year":"2017","journal-title":"Ir. J. Psychol. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40261-017-0617-x","article-title":"Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: A follow-up study","volume":"38","author":"Bozzatello","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_196","first-page":"CD005653","article-title":"Pharmacological interventions for borderline personality disorder","volume":"16","author":"Stoffers","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials","volume":"196","author":"Lieb","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jclinepi.2003.12.010","article-title":"Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials","volume":"57","author":"Boutron","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.10cs05959blu","article-title":"Complementary and alternative medicine in major depressive disorder: The American psychiatric association task force report","volume":"71","author":"Freeman","year":"2010","journal-title":"J. Clin. Psychiatry."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"European Food Safety Authority (EFSA) Panelon Dietetic Products, Nutrition and Allergies (NDA) (2012). Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J., 10, 2815.","DOI":"10.2903\/j.efsa.2012.2815"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial","volume":"39","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"key":"ref_203","first-page":"1","article-title":"Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis","volume":"89","author":"MacLean","year":"2004","journal-title":"Evid. Rep. Technol. Assess. (Summ.)"},{"key":"ref_204","first-page":"CD003205","article-title":"Omega-3 polyunsaturated fatty acids (HUFA) for type 2 diabetes mellitus","volume":"1","author":"Hartweg","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MOL.0b013e328321b3be","article-title":"Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes","volume":"20","author":"Hartweg","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1476-511X-8-36","article-title":"Effectt of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study","volume":"8","author":"Bloomer","year":"2009","journal-title":"Lipids Health Dis."},{"key":"ref_207","unstructured":"VKM (Norwegian Scientific Committee for Food Safety) (2016, June 20). Opinion of the steering committee of the norwegian scientific committee for food safety: Evaluation of negative and positive health effects of n-3 fatty acids as constituents of food supplements and fortified foods. Available online: http:\/\/english.vkm.no\/dav\/031c000d1a.pdf."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1748-5827.2010.00968.x","article-title":"Beneficial effects of omega-3 fatty acids in cardiovascular disease","volume":"51","author":"Freeman","year":"2010","journal-title":"J. Small Anim. Pract."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:41Z","timestamp":1760189321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":208,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijms20215257"],"URL":"https:\/\/doi.org\/10.3390\/ijms20215257","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]}}}